November 23, 2016 - By Marguerite Chambers · 0 Comments
The stock of Advaxis Incorporated (NASDAQ:ADXS) registered an increase of 6.37% in short interest. ADXS’s total short interest was 10.40M shares in November as published by FINRA. Its up 6.37% from 9.78M shares, reported previously. With 691,100 shares average volume, it will take short sellers 15 days to cover their ADXS’s short positions. The short interest to Advaxis Incorporated’s float is 35.04%. About 239,994 shares traded hands. Advaxis, Inc. (NASDAQ:ADXS) has declined 1.22% since April 21, 2016 and is downtrending. It has underperformed by 6.55% the S&P500.
Advaxis, Inc. is a clinical-stage biotechnology company. The company has a market cap of $374.02 million. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins. It currently has negative earnings. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Insitutional Activity: The institutional sentiment decreased to 1.72 in Q2 2016. Its down 0.66, from 2.38 in 2016Q1. The ratio dropped, as 7 funds sold all Advaxis, Inc. shares owned while 14 reduced positions. 11 funds bought stakes while 39 increased positions. They now own 21.74 million shares or 0.17% less from 21.77 million shares in 2016Q1.
Citigroup accumulated 0% or 26,234 shares. Sectoral Asset Management accumulated 433,859 shares or 0.36% of the stock. Birchview Cap Limited Partnership has invested 0.21% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Alliancebernstein Limited Partnership accumulated 0% or 54,100 shares. The Pennsylvania-based Miller Inv Management L P has invested 0.04% in Advaxis, Inc. (NASDAQ:ADXS). The New York-based Goldman Sachs Grp Inc Incorporated has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). The Connecticut-based Sarissa Capital Mgmt Lp has invested 1.38% in Advaxis, Inc. (NASDAQ:ADXS). Laurion Cap Limited Partnership holds 0% or 28,300 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 564 shares in the company. Blackrock Group Incorporated Ltd holds 29,496 shares or 0% of its portfolio. Thrivent For Lutherans, a Minnesota-based fund reported 125,900 shares. Morgan Stanley has 52,383 shares for 0% of their US portfolio. Northern Tru Corporation has 386,249 shares for 0% of their US portfolio. Jfs Wealth Ltd Liability holds 500 shares or 0% of its portfolio. Barclays Public Limited Company has 130 shares for 0% of their US portfolio.
Insider Transactions: Since August 8, 2016, the stock had 0 buys, and 5 insider sales for $1.11 million net activity. The insider SIDRANSKY DAVID sold 22,808 shares worth $342,348. On Monday, October 31 O’Connor Daniel sold $68,557 worth of the stock or 8,240 shares. $157,703 worth of Advaxis, Inc. (NASDAQ:ADXS) shares were sold by Mayes – Gregory T.. On Monday, October 31 PETIT ROBERT sold $23,271 worth of the stock or 2,797 shares. The insider BERMAN RICHARD J sold $520,755.
Out of 2 analysts covering Advaxis (NASDAQ:ADXS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Advaxis has been the topic of 2 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Overweight” rating by Barclays Capital on Tuesday, September 22. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Friday, September 11 by Guggenheim.
Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants. The Company’s immunotherapy candidates include Axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2.
Another recent and important Advaxis, Inc. (NASDAQ:ADXS) news was published by Prnewswire.com which published an article titled: “Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of …” on October 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers